Clearpoint Neuro, INC Form 4 insider transactions

Jeremy L. Stigall, Chief Business Officer of ClearPoint Neuro, Inc., was granted 77,487 restricted stock units (RSUs) on May 20, 2024, which will vest over a three-year period.

ClearPoint Neuro's CFO, Danilo D'Alessandro, reports the acquisition of 81,566 restricted stock units.

ClearPoint Neuro's CEO, Joseph Michael Burnett, received 212,071 restricted stock units on May 20, 2024, which vest over a three-year period.

Director Lynnette C. Fallon reports acquisition of 21,093 restricted stock units in ClearPoint Neuro, Inc.

Director Matthew B. Klein acquired 21,093 restricted stock units in ClearPoint Neuro, Inc. on May 16, 2024.

Director Pascal E. R. Girin acquired 21,093 restricted stock units in ClearPoint Neuro, Inc.

Director B. Kristine Johnson acquired 21,093 restricted stock units of ClearPoint Neuro, Inc. on May 16, 2024.

Director Timothy T. Richards reports acquisition of 21,093 restricted stock units in ClearPoint Neuro, Inc.

Director R. John Fletcher acquired 21,093 restricted stock units in ClearPoint Neuro, Inc.

Director Linda M. Liau reports acquisition of 21,093 restricted stock units in ClearPoint Neuro, Inc.

Director Lynnette C. Fallon reports the conversion of restricted stock units into common stock and subsequent disposal of shares.

Director R. John Fletcher converted 17,153 restricted stock units into common stock of ClearPoint Neuro, Inc.

Pascal E. R. Girin, a director of ClearPoint Neuro, Inc., converted 17,153 restricted stock units into common stock on May 14, 2024.

Director Matthew Klein converted 17,153 restricted stock units into common stock on May 14, 2024.

Director B. Kristine Johnson reports the conversion of restricted stock units into common stock and subsequent disposal of shares.

Director Linda M. Liau reports the conversion of restricted stock units into common stock and subsequent disposal of shares at ClearPoint Neuro, Inc.

Director Timothy T. Richards reports the conversion of restricted stock units into common stock.

Director R. John Fletcher acquired 850 shares of ClearPoint Neuro, Inc. as compensation under the company's Non-Employee Director Compensation Plan.

Pascal E. R. Girin, a director at ClearPoint Neuro, acquired 1,056 shares of common stock on April 1, 2024, as payment for director fees.

Director Linda M. Liau acquired 436 shares of ClearPoint Neuro, Inc. common stock on April 1, 2024, as payment for fees under the company's Non-Employee Director Compensation Plan.

Director Timothy T. Richards acquired 1,640 shares of ClearPoint Neuro, Inc. common stock on April 1, 2024, as payment for fees under the company's Non-Employee Director Compensation Plan.

ClearPoint Neuro's Chief Business Officer, L. Jeremy Stigall, acquired 16,583 restricted stock units on March 11, 2024, according to a recent SEC filing.

ClearPoint Neuro's CFO, Danilo D'Alessandro, reports the acquisition of 8,291 restricted stock units.

ClearPoint Neuro's Chief Operating Officer, Mazin Sabra, reports the acquisition and disposal of company stock and restricted stock units on March 6, 2024.

ClearPoint Neuro's Chief Business Officer, Jeremy L. Stigall, exercised stock options and disposed of shares to cover tax obligations on March 6, 2024.

ClearPoint Neuro's CFO, Danilo D'Alessandro, reports the acquisition and disposal of company stock, including the settlement of restricted stock units for tax obligations.

CEO Joseph Burnett of ClearPoint Neuro, Inc. reports the acquisition and disposal of common stock and restricted stock units on March 6, 2024.